Forskning ved Københavns Universitet - Københavns Universitet

Forside

Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. / Hebert, Katrine P; Klarskov, Niels; Bagi, Per; Biering-Sørensen, Fin; Elmelund, Marlene.

I: Spinal Cord, Bind 58, Nr. 6, 2020, s. 675-681.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Hebert, KP, Klarskov, N, Bagi, P, Biering-Sørensen, F & Elmelund, M 2020, 'Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury', Spinal Cord, bind 58, nr. 6, s. 675-681. https://doi.org/10.1038/s41393-019-0411-0

APA

Hebert, K. P., Klarskov, N., Bagi, P., Biering-Sørensen, F., & Elmelund, M. (2020). Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord, 58(6), 675-681. https://doi.org/10.1038/s41393-019-0411-0

Vancouver

Hebert KP, Klarskov N, Bagi P, Biering-Sørensen F, Elmelund M. Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. Spinal Cord. 2020;58(6):675-681. https://doi.org/10.1038/s41393-019-0411-0

Author

Hebert, Katrine P ; Klarskov, Niels ; Bagi, Per ; Biering-Sørensen, Fin ; Elmelund, Marlene. / Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury. I: Spinal Cord. 2020 ; Bind 58, Nr. 6. s. 675-681.

Bibtex

@article{937106cf1f0a4a6592d4fe7a113cae05,
title = "Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury",
abstract = "STUDY DESIGN: Retrospective chart study.OBJECTIVES: The aim was to examine continuation of treatment of individuals with spinal cord injury including myelomeningocele and neurogenic detrusor overactivity, treated with repeated intra-detrusor Botulinum toxin A injections, and to investigate factors associated with discontinuation of treatment.SETTING: Rigshospitalet, Denmark METHODS: This study included 128 individuals with spinal cord injury and neurogenic detrusor overactivity, who were offered repeated Botulinum toxin A injections between 2001 and 2018. Continuation rates of the treatment were estimated using Kaplan Meier analysis. A Cox proportional hazard analysis was used to investigate factors predictive of discontinuation.RESULTS: A total of 1156 treatments were performed. The median number of treatments was six (IQR 9, range 1-51), and median follow-up was 10.6 years (IQR 8.5, range 0-16.9). All urodynamic parameters changed significantly after the first treatment (p < 0.001). The continuation group had significantly higher mean maximum bladder capacity after the first injections compared with the discontinuation group, with a mean difference between the groups of 84.5 mL (95% CI 4.7-164.2) (p = 0.038). The probability of continuing treatments after 5 years was 59% (95% CI 50.0-67.8) and 50% (95% CI 40.1-59.3) after 10 years. Individuals aged 31-50 years were more likely to continue treatment compared with those aged >50 years (95% CI 0.21‒0.79) (p = 0.008). No other factors predicted discontinuation.CONCLUSIONS: This long-term follow-up study showed that 50% of people with spinal cord injury starting intra-detrusor Botulinum toxin A for neurogenic detrusor overactivity are still receiving injections after 10 years.",
author = "Hebert, {Katrine P} and Niels Klarskov and Per Bagi and Fin Biering-S{\o}rensen and Marlene Elmelund",
year = "2020",
doi = "10.1038/s41393-019-0411-0",
language = "English",
volume = "58",
pages = "675--681",
journal = "Spinal Cord",
issn = "1362-4393",
publisher = "nature publishing group",
number = "6",

}

RIS

TY - JOUR

T1 - Long term continuation with repeated Botulinum toxin A injections in people with neurogenic detrusor overactivity after spinal cord injury

AU - Hebert, Katrine P

AU - Klarskov, Niels

AU - Bagi, Per

AU - Biering-Sørensen, Fin

AU - Elmelund, Marlene

PY - 2020

Y1 - 2020

N2 - STUDY DESIGN: Retrospective chart study.OBJECTIVES: The aim was to examine continuation of treatment of individuals with spinal cord injury including myelomeningocele and neurogenic detrusor overactivity, treated with repeated intra-detrusor Botulinum toxin A injections, and to investigate factors associated with discontinuation of treatment.SETTING: Rigshospitalet, Denmark METHODS: This study included 128 individuals with spinal cord injury and neurogenic detrusor overactivity, who were offered repeated Botulinum toxin A injections between 2001 and 2018. Continuation rates of the treatment were estimated using Kaplan Meier analysis. A Cox proportional hazard analysis was used to investigate factors predictive of discontinuation.RESULTS: A total of 1156 treatments were performed. The median number of treatments was six (IQR 9, range 1-51), and median follow-up was 10.6 years (IQR 8.5, range 0-16.9). All urodynamic parameters changed significantly after the first treatment (p < 0.001). The continuation group had significantly higher mean maximum bladder capacity after the first injections compared with the discontinuation group, with a mean difference between the groups of 84.5 mL (95% CI 4.7-164.2) (p = 0.038). The probability of continuing treatments after 5 years was 59% (95% CI 50.0-67.8) and 50% (95% CI 40.1-59.3) after 10 years. Individuals aged 31-50 years were more likely to continue treatment compared with those aged >50 years (95% CI 0.21‒0.79) (p = 0.008). No other factors predicted discontinuation.CONCLUSIONS: This long-term follow-up study showed that 50% of people with spinal cord injury starting intra-detrusor Botulinum toxin A for neurogenic detrusor overactivity are still receiving injections after 10 years.

AB - STUDY DESIGN: Retrospective chart study.OBJECTIVES: The aim was to examine continuation of treatment of individuals with spinal cord injury including myelomeningocele and neurogenic detrusor overactivity, treated with repeated intra-detrusor Botulinum toxin A injections, and to investigate factors associated with discontinuation of treatment.SETTING: Rigshospitalet, Denmark METHODS: This study included 128 individuals with spinal cord injury and neurogenic detrusor overactivity, who were offered repeated Botulinum toxin A injections between 2001 and 2018. Continuation rates of the treatment were estimated using Kaplan Meier analysis. A Cox proportional hazard analysis was used to investigate factors predictive of discontinuation.RESULTS: A total of 1156 treatments were performed. The median number of treatments was six (IQR 9, range 1-51), and median follow-up was 10.6 years (IQR 8.5, range 0-16.9). All urodynamic parameters changed significantly after the first treatment (p < 0.001). The continuation group had significantly higher mean maximum bladder capacity after the first injections compared with the discontinuation group, with a mean difference between the groups of 84.5 mL (95% CI 4.7-164.2) (p = 0.038). The probability of continuing treatments after 5 years was 59% (95% CI 50.0-67.8) and 50% (95% CI 40.1-59.3) after 10 years. Individuals aged 31-50 years were more likely to continue treatment compared with those aged >50 years (95% CI 0.21‒0.79) (p = 0.008). No other factors predicted discontinuation.CONCLUSIONS: This long-term follow-up study showed that 50% of people with spinal cord injury starting intra-detrusor Botulinum toxin A for neurogenic detrusor overactivity are still receiving injections after 10 years.

U2 - 10.1038/s41393-019-0411-0

DO - 10.1038/s41393-019-0411-0

M3 - Journal article

C2 - 31913344

VL - 58

SP - 675

EP - 681

JO - Spinal Cord

JF - Spinal Cord

SN - 1362-4393

IS - 6

ER -

ID: 257197487